Abstract 4543
Background
IPI has shown durable overall survival (OS) in patients (pts) with MEL in clinical trials, but robust RW evidence is lacking. We present long-term RW outcomes from the IMAGE study (NCT01511913) in which pts received IPI and non-IPI therapies.
Methods
IMAGE was a large, multinational, prospective, observational study that enrolled adult pts with MEL treated with IPI or non-IPI from June 2012 to March 2015 and included > 3 years of follow-up. Adjusted OS curves were based on multivariate Cox regression models by adjusting for covariate effects. Progression-free survival (PFS) was analyzed using Kaplan-Meier methods. Patients self-administered the EORTC QLQ-C30, a validated, cancer-specific, health-related quality of life (QoL) questionnaire.
Results
Of 1356 pts, 1094 (81%) received IPI and 262 (19%) received non-IPI as index therapy. In all pts, median age was 64 years, 60% were male, 78% were from the EU, median time on study was 6 months, and 78% were pretreated (received ≥ 2 lines of therapy). In the IPI cohort, 780 pts (71%) remained on IPI and 314 (29%) switched to non-IPI. In the non-IPI cohort, 205 pts (78%) remained on non-IPI and 57 (22%) switched to IPI. Among 1151 pts who received IPI, 26% reported grade ≥ 3 treatment-related adverse events (AEs); most AEs occurred during year 1. The 3-year OS rates were 28% in the IPI and 25% in the non-IPI cohorts. In pretreated pts, OS rates were 25% in the IPI and 23% in the non-IPI cohorts. However, in treatment-naive pts, the OS rate in the IPI cohort was 40% compared with 33% in the non-IPI cohort, although the small sample size limits interpretation. Median PFS was 3 months in both the IPI and non-IPI cohorts. Completion rates for EORTC QLQ-C30 Global Health Status (GHS) score were 58%–80%. No major differences were observed in changes from baseline for EORTC QLQ-C30 GHS scores between the IPI and non-IPI cohorts, with similar trends of initial worsening and subsequent improvement.
Conclusions
Long-term, RW outcomes from IMAGE were consistent with those from IPI clinical trials. OS analysis across treatment-naive and pretreated pts suggested a beneficial role of IPI early in the disease with no detrimental impact on QoL.
Clinical trial identification
NCT01511913.
Editorial acknowledgement
Kakoli Parai, PhD, and Andrea Lockett at StemScientific, an Ashfield Company, funded by Bristol-Myers Squibb.
Legal entity responsible for the study
Bristol-Myers Squibb.
Funding
Bristol-Myers Squibb.
Disclosure
S. Dalle: Advisory / Consultancy, Research grant / Funding (self): Bristol-Myers Squibb; Research grant / Funding (self): Merck, Sharp & Dohme. L. Mortier: Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: GlaxoSmithKline; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: LEO Pharma; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Merck, Sharp & Dohme. P. Corrie: Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Merck, Sharp & Dohme; Honoraria (self), Advisory / Consultancy: Pierre Fabre; Advisory / Consultancy: Incyte. R. Board: Honoraria (self), Advisory / Consultancy: Merck, Sharp & Dohme; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Pierre Fabre. A.M. Arance: Travel / Accommodation / Expenses: Bristol-Myers Squibb; Travel / Accommodation / Expenses: Merck, Sharp & Dohme; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Novartis; Travel / Accommodation / Expenses: Merck. F. Meiss: Honoraria (self), Non-remunerated activity/ies: Bristol-Myers Squibb. P. Terheyden: Research grant / Funding (self): Bristol-Myers Squibb. R. Gutzmer: Research grant / Funding (institution): Bristol-Myers Squibb. J. Brokaw: Full / Part-time employment: Bristol-Myers Squibb. T.K. Le: Full / Part-time employment: Bristol-Myers Squibb. J. Scotto: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. J. Lord-Bessen: Full / Part-time employment: Bristol-Myers Squibb. A. Moshyk: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. S. Kotapati: Shareholder / Stockholder / Stock options, Full / Part-time employment: Bristol-Myers Squibb. M.R. Middleton: Advisory / Consultancy: Amgen, GlaxoSmithKline, Novartis, Roche; Research grant / Funding (institution): AstraZeneca, GlaxoSmithKline, Novartis, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
5822 - Greek nursing students experience facing death in clinical practice
Presenter: Maria Dimoula
Session: Poster Display session 3
Resources:
Abstract
2866 - HOPEVOL: Hospice care appropriate to the wishes and needs of patients in the palliative terminal phase.
Presenter: Merel van Klinken
Session: Poster Display session 3
Resources:
Abstract
829 - Mindfulness-based stress reduction in early palliative care for advanced cancer patients : an italian single-centre study. MINDEEP
Presenter: Emilia Gianotti
Session: Poster Display session 3
Resources:
Abstract
2702 - Optimising Inpatient Oncology Care
Presenter: Lisa Judge
Session: Poster Display session 3
Resources:
Abstract
1527 - Analysis on the Implementation Results of Family Sickbed for Oncology Patients in Dongshi Township Health Centers from 2015 to 2017
Presenter: Yayu Huang
Session: Poster Display session 3
Resources:
Abstract
2054 - Exploring needs for palliative care and quality of life for oncology patients with advanced disease who undergo radiotherapy
Presenter: Foteini Antonopoulou
Session: Poster Display session 3
Resources:
Abstract
5605 - Cytotoxic contamination in cancer care settings – Risks and safety awareness among cancer nurses
Presenter: Sandra Lundman Vikberg
Session: Poster Display session 3
Resources:
Abstract
5769 - Understanding Chemotherapy - group education sessions prior to commencing chemotherapy
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
2620 - Estimation of HPQ-based absenteeism and presenteeism in cancer patients via ResearchKit
Presenter: Shunsuke Kondo
Session: Poster Display session 3
Resources:
Abstract
4705 - Identifying falls-related variables and risk factors in hospitalised cancer patients
Presenter: Maria Montserrat Martí Dillet
Session: Poster Display session 3
Resources:
Abstract